VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Friday, January 2, 2026

Stock Comparison

Keyence Corporation vs Abbott Laboratories

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Keyence Corporation

6861.T · Tokyo Stock Exchange

Market cap (USD)$87.6B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorTechnology
Industry
CountryJP
Data as of2026-01-02
Moat score
73/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Keyence Corporation's moat claims, evidence, and risks.

View 6861.T analysis

Abbott Laboratories

ABT · New York Stock Exchange

Market cap (USD)$215.9B
Gross margin (TTM)54%
Operating margin (TTM)17.7%
Net margin (TTM)31.9%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2025-12-30
Moat score
64/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Abbott Laboratories's moat claims, evidence, and risks.

View ABT analysis

Comparison highlights

  • Moat score gap: Keyence Corporation leads (73 / 100 vs 64 / 100 for Abbott Laboratories).
  • Segment focus: Keyence Corporation has 3 segments; Abbott Laboratories has 7 segments (26.7% in Cardiovascular & Electrophysiology Devices).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
  • Moat breadth: Keyence Corporation has 7 moat types across 2 domains; Abbott Laboratories has 10 across 3.

Primary market context

Keyence Corporation

Sensors & Safety/Static Control

Market

Industrial sensors and safety/static control for factory automation

Geography

Global

Customer

Manufacturers (production/automation teams) and machine builders

Role

Component OEM and application-solution provider

Abbott Laboratories

Cardiovascular & Electrophysiology Devices

Market

Cardiovascular, electrophysiology, rhythm management, structural heart and heart failure devices

Geography

Global

Customer

Hospitals, ambulatory surgery centers, cardiologists/electrophysiologists

Role

Implantable device manufacturer

Revenue share

26.7%

Side-by-side metrics

Keyence Corporation
Abbott Laboratories
Ticker / Exchange
6861.T - Tokyo Stock Exchange
ABT - New York Stock Exchange
Market cap (USD)
$87.6B
$215.9B
Gross margin (TTM)
n/a
54%
Operating margin (TTM)
n/a
17.7%
Net margin (TTM)
n/a
31.9%
Sector
Technology
Healthcare
Industry
n/a
Medical - Devices
HQ country
JP
US
Primary segment
Sensors & Safety/Static Control
Cardiovascular & Electrophysiology Devices
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Moderate
Moat score
73 / 100
64 / 100
Moat domains
Supply, Demand
Demand, Legal, Supply
Last update
2026-01-02
2025-12-30

Moat coverage

Shared moat types

Distribution ControlBrand Trust

Keyence Corporation strengths

Service Field NetworkDesign In QualificationLearning Curve YieldOperational ExcellenceScope Economies

Abbott Laboratories strengths

Procurement InertiaInstalled Base ConsumablesData Workflow LockinGovernment Contracting RelationshipsCompliance AdvantageScale Economies Unit CostTraining Org Change CostsIP Choke Point

Segment mix

Keyence Corporation segments

Full profile >

Sensors & Safety/Static Control

Oligopoly

n/a

Machine Vision, Code Reading & Laser Marking

Oligopoly

n/a

Metrology & Microscopes

Oligopoly

n/a

Abbott Laboratories segments

Full profile >

Established Pharmaceutical Products

Competitive

12.4%

Diagnostic Products

Oligopoly

22.3%

Pediatric Nutrition

Oligopoly

9.6%

Adult Nutrition

Oligopoly

10.5%

Diabetes Care (CGM & glucose monitoring)

Duopoly

16.2%

Cardiovascular & Electrophysiology Devices

Oligopoly

26.7%

Neuromodulation Devices

Oligopoly

2.3%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.